Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIST4721 in Palmoplantar Pustulosis
NCT03988335Phase 2Completed
- Sponsor
- Aristea Therapeutics
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in palmoplantar pustulosis (PPP) comparing RIST4721 with Placebo (2 arms). Primary endpoints: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline and Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to Baseline. Started Feb 2019; status: completed.
02
Drugs
vimnerixin
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT03988335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988335.